HER2 Breast Cancer

Experts from Sarah Cannon Research Institute talk about the expanding role of targeted treatment options in early HER2+ breast cancer.

Ian E. Krop, MD, PhD, discusses the importance of clinical trials further exploring the role of trastuzumab deruxtecan following the FDA’s approval of the agent as treatment of patients with HER2-positive metastatic breast cancer.

The FDA has approved the Ventana HER2 Dual ISH DNA Probe Cocktail assay as a companion diagnostic for trastuzumab and for the detection of the HER2 biomarker in patients with breast cancer.

Neratinib plus capecitabine improved progression-free survival and time to intervention for central nervous system disease in patients with previously treated HER2-positive metastatic breast cancer compared with lapatinib plus capecitabine, results from the phase 3 NALA trial show.

A key opinion leader discusses how the role tucatinib is evolving in the management of HER2-positive metastatic breast cancer.

An exploratory analysis of trastuzumab emtansine demonstrated activity and tolerability in patients with HER2-positive locally advanced or metastatic breast cancer who have brain metastases participating in the prospective KAMILLA trial.

Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.

Nancy U. Lin, MD, discusses the latest findings from the HER2CLIMB study of either tucatinib or placebo, added to trastuzumab and capecitabine, for patients with previously treated HER2-positive metastatic breast cancer who have brain metastases.

"The FDA approval of Phesgo reflects our commitment to improving outcomes for the many people living with HER2-positive breast cancer."

In a single-institution study, investigators found a correlation between certain genotypes and comorbidities and trastuzumab-induced cardiotoxicity among patients with HER2-positive breast cancer.